Arm Shares Fall Over 3% After Qualcomm Wins License Dispute 
Nvidia’s China AI Chip Market Share Falls to 34% as Huawei Gains Ground 
OpenAI Uses AI to Uncover Hidden Recording Device, FBI Makes Arrest 
Bumble Shares Surge 50% on $1 Billion Buyout Talks 
NEAR Protocol Leads AI Crypto Rally Amid Fed Rate Hike Fears 
IMF, World Bank Meetings Face Global Economic Risks Amid Iran War 
Syndax Stock Drops 15% After Axatilimab Trial Failure 
Interactive Brokers Launches Ethereum Staking With Zerohash 
Samsung, SK Hynix Shares Plunge as China Chip Competition Grows 
Asian Currencies Steady as Dollar Nears 18-Month High Ahead of US CPI 
Nvidia Invests in Four French AI Companies to Expand European Presence 
Canton Network Expands Wall Street Reach With Ripple Integration 
Fed's Hammack Urges Faster Rate Hikes to Fight Inflation 
Visa Wins China Approval to Prepare Domestic Payments Expansion 
Wall Street Ends Mixed as Investors Await CPI and Bank Earnings 
Fed’s Williams Sees One More Rate Hike in 2026, None in 2027 
US Dollar Index Falls as Fed Signals Caution, Indian Rupee Surges 
Add as a preferred source on Google
Pfizer announced on Wednesday, April 28, that it has acquired Amplyx Pharmaceuticals. The company stated that the purchase would bolster its portfolio as it offers the opportunity to strengthen “Pfizer’s expertise and deep heritage in infectious disease.”
As per Reuters, Amplyx Pharmaceuticals is based in San Diego, and it is developing new treatments against drug-resistant microbes in patients with compromised immune systems.
The anti-fungal drug has been named fosmanogepix, and it is now in the second phase of clinical trials.
Pfizer to continue testing on Amplyx’s experimental drug
The New York-headquartered multinational pharmaceutical company acquired Amplyx while it is in the middle of conducting trials for its anti-fungal drug that is hoped to effectively fight off drug-resistant infections that ravage the immune system of patients. Since this is the case, Pfizer will not abandon but continue the clinical trials of this experimental drug.
If Amplyx's fosmanogepix drug will show good results and eventually be approved, it will become the first type of new antifungal treatment to come in the last 20 years. This is an important drug because it can kill fungi, like bacteria, that have turned resistant to common drugs or medicines.
Why Pfizer is further expanding its infectious disease folio
It was estimated that if this kind of drug will not be developed, drug-resistant superbugs may possibly kill at least 10 million people by 2050. This is why Pfizer has been expanding its portfolio for treatments that can fight these threatening superbugs.
Pfizer noted that hospitalized patients’ immune systems tend to become weaker since the drugs they take do not work, and this has become a problem not just for the ill but for doctors as well. This scenario just showed how much people need effective anti-fungal treatments for such patients.
“The COVID-19 pandemic has been a stark reminder of the devastating impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral and fungal infections,” Pfizer Hospital’s global president, Angela Lukin, said in a press release. “We are deeply committed to helping patients suffering from infectious diseases, continuously seeking opportunities to build our portfolio of anti-infective therapies.”
